Too high price for drugs for cystic fibrosis

TLV

25 March 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, says no to subsidising the drugs Kaftrio and Kalydeco for cystic fibrosis because the price the company is asking for is far above what is reasonable.

Based on the company's applied price and basis, the cost is much higher than for other drugs for equally serious diseases. TLV has had tripartite discussions with the company and the regions about Kaftrio and Kalydeco. However, the company and the regions have not reached a side agreement that could have reduced the costs of the treatments and thus influenced the decision to subsidize Kaftrio and Kalydeco.

Read TLV press release

Michael Wonder

Posted by:

Michael Wonder